EcoDrugPlus

Purinergic Receptor P2x 3

Ensembl ID : ENSMLUG00000007190
Gene Symbol: P2RX3
4 Cross references
270 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSMLUG00000027366
Gene Symbol: P2RY1
2 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSMLUG00000011489
Gene Symbol: P2RY12
2 Cross references
180 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSMLUG00000002983
Gene Symbol: P2RY2
2 Cross references
197 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSMLUG00000011018
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSMLUG00000025955
Gene Symbol: P2RY6
2 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSMLUG00000002016
Gene Symbol: RAMP1
2 Cross references
253 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMLUG00000016163
Gene Symbol: RIPK1
2 Cross references
197 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSMLUG00000008904
Gene Symbol: RPTOR
2 Cross references
209 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSMLUG00000017458
Gene Symbol: RET
2 Cross references
204 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSMLUG00000007782
Gene Symbol: RARA
2 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSMLUG00000001683
Gene Symbol: RARB
2 Cross references
450 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).